NIOX Group Investor Relations Material

NIOX Group Plc is a medical device company focused on the diagnosis and management of respiratory diseases, with a particular emphasis on asthma. The company's flagship product, NIOX VERO, is a non-invasive, point-of-care device designed for the measurement of fractional exhaled nitric oxide, which is a biomarker for airway inflammation in asthma patients. This device aids healthcare professionals in diagnosing and managing asthma by providing precise FeNO measurements. The company is headquartered in Oxford, United Kingdom, and its shares are listed on the London Stock Exchange.